OPHTHALMIC DRUGS MARKET ANALYSIS

Leading Companies

Global Ophthalmic Drugs Market: Key Developments

In May 2022, Alcon signed an agreement to acquire EYSUVIS (loteprednol etabonate suspension) pharmaceutical eye drops from Kala Pharmaceuticals, Inc. This acquisition will enhance Alcon’s current offering in the large and currently growing dry eye segment.

In April 2022, Sandoz launched generic combination eyedrop brimonidine tartrate/timolol maleate ophthalmic solution, an AB-rated generic equivalent to AbbVie’s COMBIGAN, to lower the eye pressure in patients with ocular hypertension (high eye pressure) in the United States.

In March 2022, Théa Pharma acquired seven branded ophthalmic products from Akorn Operating Company LLC to strengthen its position as a significant provider of products developed to satisfy the demands of eye care specialists across the United States.

In January 2022, Sun Pharma Canada Inc. launched Cequa (cyclosporine ophthalmic solution 0.09 percent w/v), a calcineurin inhibitor immunomodulator, to treat dry eye disease in Canada.

Global Ophthalmic Drugs Market: Key Companies Insights

The global ophthalmic drugs market is highly competitive. This is attributed to the rise in demand for safe, effective ophthalmic drugs across the world, as a result, players in the market are focusing on launching novel products in the market.

Some of the key players in the global ophthalmic drugs market are Abbvie Inc. (Allergan Plc), Alcon, Inc., Novartis AG, Pfizer Inc., Bausch & Lomb Incorporated, F. Hoffmann-LA Roche Ltd. (Genentech, Inc.), among others.